🏛️ Verified NIH Record • Updated 2026-07-02

A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer (NCT05908734)

A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Cetrelimab Combination Therapy in Metastatic Non-small Cell Lung Cancer

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Janssen Research & Development, LLC

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD) of the amivantamab and cetrelimab combination therapy in participants with non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection); and to evaluate the antitumor effect of the combination at the selected RP2CD in participants with NSCLC characterized on the basis of epidermal growth factor receptor (EGFR) and Programmed-cell death Ligand (PD-L)1 status, in the Phase 2 (expansion).

Who can join: Review the eligibility criteria below.

Location: City of Hope — Duarte, California

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (44 Sites)

Showing the first 25 of 44 sites.

  • City of Hope — Duarte, California
  • City of Hope Orange County Lennar Foundation Cancer Center — Irvine, California
  • Cancer and Blood Specialty Clinic — Los Alamitos, California
  • Providence Portland Medical Center — Portland, Oregon
  • Providence Oncology and Hematology Care Clinic Westside — Portland, Oregon
  • MD Anderson Cancer Center — Houston, Texas
  • Virginia Cancer Specialists — Fairfax, Virginia
  • Fundacao Pio XII — Barretos,
  • Cetus Oncologia — Belo Horizonte,
  • PERSONAL Oncologia de Precisao e Personalizada — Belo Horizonte,
  • CIONC Centro Integrado de Oncologia de Curitiba — Curitiba,
  • Hospital do Cancer de Londrina — Londrina,
  • Hospital Nossa Senhora da Conceicao S A — Porto Alegre,
  • Hospital Santa Izabel Santa Casa de Misericordia da Bahia — Salvador,
  • Fundacao Antonio Prudente A C Camargo Cancer Center — São Paulo,
  • European Institute of Oncology — Milan,
  • ASST Grande Ospedale Metropolitano Niguarda — Milan,
  • Aou San Luigi Gonzaga — Orbassano,
  • Centro Ricerche Cliniche di Verona S r l — Verona,
  • University Malaya Medical Centre — Kuala Lumpur,
  • Hospital Umum Sarawak — Kuching,
  • INSTYTUT GENETYKI I IMMUNOLOGII GENIM Sp z o o — Lublin,
  • Wielkopolskie Centrum Pulmonologii i Torakochirurgii im. Eugenii i Janusza Zeylandow — Poznan,
  • Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy — Warsaw,
  • Seoul National University Hospital — Seoul,

📞 Contact the Study Coordinator

Phone: (800) 826-4673

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Carcinoma, Non-Small-Cell Lung

Explore by condition: All Carcinoma, Non-Small-Cell Lung clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗